BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27479756)

  • 1. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
    Kishimoto TK; Ferrari JD; LaMothe RA; Kolte PN; Griset AP; O'Neil C; Chan V; Browning E; Chalishazar A; Kuhlman W; Fu FN; Viseux N; Altreuter DH; Johnston L; Maldonado RA
    Nat Nanotechnol; 2016 Oct; 11(10):890-899. PubMed ID: 27479756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
    Kishimoto TK
    Front Immunol; 2020; 11():969. PubMed ID: 32508839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
    Maldonado RA; LaMothe RA; Ferrari JD; Zhang AH; Rossi RJ; Kolte PN; Griset AP; O'Neil C; Altreuter DH; Browning E; Johnston L; Farokhzad OC; Langer R; Scott DW; von Andrian UH; Kishimoto TK
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E156-65. PubMed ID: 25548186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.
    Srivastava A; Arlian BM; Pang L; Kishimoto TK; Paulson JC
    ACS Chem Biol; 2021 Oct; 16(10):1985-1993. PubMed ID: 34037371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance.
    Kim WU; Lee WK; Ryoo JW; Kim SH; Kim J; Youn J; Min SY; Bae EY; Hwang SY; Park SH; Cho CS; Park JS; Kim HY
    Arthritis Rheum; 2002 Apr; 46(4):1109-20. PubMed ID: 11953991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation.
    Zhang AH; Rossi RJ; Yoon J; Wang H; Scott DW
    Cell Immunol; 2016 Mar; 301():74-81. PubMed ID: 26687613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.
    Kishimoto TK; Maldonado RA
    Front Immunol; 2018; 9():230. PubMed ID: 29515571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124.
    Molavi O; Ma Z; Hamdy S; Lavasanifar A; Samuel J
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):214-21. PubMed ID: 18798092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.
    LaMothe RA; Kolte PN; Vo T; Ferrari JD; Gelsinger TC; Wong J; Chan VT; Ahmed S; Srinivasan A; Deitemeyer P; Maldonado RA; Kishimoto TK
    Front Immunol; 2018; 9():281. PubMed ID: 29552007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
    Sands E; Kivitz A; DeHaan W; Leung SS; Johnston L; Kishimoto TK
    Nat Commun; 2022 Jan; 13(1):272. PubMed ID: 35022448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Injection of Myelin Oligodendrocyte Glycoprotein-coated PLGA Microparticles Have Tolerogenic Effects in Experimental Autoimmune Encephalomyelitis.
    Gholamzad M; Ebtekar M; Shafiee Ardestani M
    Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):271-281. PubMed ID: 28732440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease.
    Cappellano G; Comi C; Chiocchetti A; Dianzani U
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.
    Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
    Curr Pharm Des; 2015; 21(29):4201-16. PubMed ID: 26323429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model.
    te Boekhorst BC; Jensen LB; Colombo S; Varkouhi AK; Schiffelers RM; Lammers T; Storm G; Nielsen HM; Strijkers GJ; Foged C; Nicolay K
    J Control Release; 2012 Aug; 161(3):772-80. PubMed ID: 22580113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.
    Cho JJ; Stewart JM; Drashansky TT; Brusko MA; Zuniga AN; Lorentsen KJ; Keselowsky BG; Avram D
    Biomaterials; 2017 Oct; 143():79-92. PubMed ID: 28772190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles.
    Campbell DF; Saenz R; Bharati IS; Seible D; Zhang L; Esener S; Messmer B; Larsson M; Messmer D
    Breast Cancer Res; 2015 Mar; 17(1):48. PubMed ID: 25882711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
    Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
    Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.
    Prasad S; Xu D; Miller SD
    Rev Diabet Stud; 2012; 9(4):319-27. PubMed ID: 23804269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles for intraarterial local drug delivery: preparation, characterization, and in vitro/in vivo release].
    Miao LF; Yang J; Huang CL; Song CX; Zeng YJ; Chen LF; Zhu WL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):491-7. PubMed ID: 18795627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.